Company profile for DNDi

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

A not-for-profit research and development organization, DNDi works to develop new treatments for people living with neglected diseases, notably Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, pediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments, including new drug combinations for kala-azar, two fixed-dose antimalar...
A not-for-profit research and development organization, DNDi works to develop new treatments for people living with neglected diseases, notably Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, pediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments, including new drug combinations for kala-azar, two fixed-dose antimalarials, DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
15 Chemin Louis-Dunant 1202 Geneva
Telephone
Telephone
+41 22 906 9230
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250723721725/en/AN2-Therapeutics-and-DNDi-Collaborate-on-Clinical-Development-of-Promising-New-Oral-Compound-to-Treat-Chronic-Chagas-Disease

BUSINESSWIRE
23 Jul 2025

https://health.economictimes.indiatimes.com/news/pharma/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-children-with-hiv/92216747

ECONOMIC TIMES
15 Jun 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty